CellSeed

CellSeed Acquisitions (Net)

The Acquisitions (Net) of CellSeed (7776.T) as of Oct 27, 2026 is 77.95 M JPY. In the previous year, Acquisitions (Net) was 77.32 M JPY — a change of 0.81% (higher).

Acquisitions (Net)

77.95 MJPY

YoY

0.81%

Last updated:

Acquisitions (Net) of CellSeed is 2023 77.95 M JPY. Acquisitions (Net) of CellSeed was 2022 77.32 M JPY. It decreases by 0.81% higher compared to the previous year.

The CellSeed Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2014
0.00 JPY
Jan 1, 2015
-29.87 M JPY
Jan 1, 2016
625,000.00 JPY
Jan 1, 2019
-119.80 M JPY
Jan 1, 2020
-2.33 M JPY
Jan 1, 2021
-19.44 M JPY
Jan 1, 2022
77.32 M JPY
Jan 1, 2023
77.95 M JPY
The CellSeed Acquisitions (Net) history
YEARAcquisitions (Net)YoY
77.95 MJPY+0.81%
77.32 MJPY-497.79%
-19.44 MJPY+733.85%
-2.33 MJPY-98.05%
-119.80 MJPY-19,268.00%
625,000.00JPY-102.09%
-29.87 MJPY—
0.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

Acquisitions (Net) of CellSeed is 77.95 M JPY in 2023.

Acquisitions (Net) of CellSeed changed from 77.32 M JPY to 77.95 M JPY, representing a 0.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) CellSeed since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s CellSeed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSeed

All Key Metrics — CellSeed